1. The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer.
- Author
-
Hsu WH, Shiau BW, Tsai YW, Wu JY, Huang PY, Chuang MH, Liu TH, Lai CC, and Weng TC
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Administration, Oral, Hospitalization statistics & numerical data, COVID-19 mortality, Hydroxylamines therapeutic use, Hydroxylamines administration & dosage, Treatment Outcome, Drug Combinations, Cytidine analogs & derivatives, Antiviral Agents therapeutic use, Antiviral Agents administration & dosage, Lung Neoplasms drug therapy, Lung Neoplasms mortality, Ritonavir therapeutic use, Ritonavir administration & dosage, COVID-19 Drug Treatment, SARS-CoV-2
- Abstract
Backgrounds: The effectiveness of oral antiviral therapy including nirmatrelvir plus ritonavir and molnupiravir in managing COVID-19 among individuals with pre-existing lung cancer was unclear. Therefore, this study was conducted to evaluate the usefulness of antiviral agents in the management of COVID-19 among patients with lung cancer., Methods: Utilizing data from the TriNetX - a global health research network, a retrospective cohort study was conducted involving 2484 patients diagnosed with both lung cancer and COVID-19. Propensity score matching (PSM) was employed to create well-balanced cohorts. The study assessed the primary outcome of all-cause hospitalization or mortality within a 30-day follow-up., Results: After PSM, the oral antiviral group exhibited a significantly lower risk of the primary composite outcome compared to the control group (6.1 % vs. 9.9 %; HR: 0.60; 95 % CI: 0.45-0.80). This association was consistent across various subgroups according to age, sex, vaccine status, type of oral antiviral agent, and lung cancer characteristics. Additionally, the oral antiviral group showed a lower risk of all-cause hospitalization (HR: 0.73; 95 % CI: 0.54-0.99) and a significantly lower risk of mortality (HR: 0.16; 95 % CI: 0.06-0.41)., Conclusion: The study suggests a favorable impact of oral antiviral therapy on the outcomes of COVID-19 in individuals with lung cancer and support the potential utility of oral antiviral agents in improving outcomes in this vulnerable population., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF